Show simple item record

dc.contributor.authorDanza, Álvaro
dc.contributor.authorGraña, Diego
dc.contributor.authorGoñi, Mabel
dc.contributor.authorVargas, Andrea
dc.contributor.authorRuiz-Irastorza, Guillermo
dc.date.accessioned2018-02-14T15:46:47Z
dc.date.available2018-02-14T15:46:47Z
dc.date.issued2016-02
dc.identifier.citationRevista Médica de Chile 144(2) : 232-240 (2016)es_ES
dc.identifier.issn0034-9887
dc.identifier.issn0717-6163
dc.identifier.urihttp://hdl.handle.net/10810/25054
dc.description.abstractHydroxychloroquine (HCQ) is by far the most frequently used antimalarial for the management of Systemic Autoimmune Diseases. It has immunomodulatory, hypolipidemic, hypoglycemic and antithrombotic properties and it diminishes the risk of malignancies. The most important mechanisms to explain the immunomodulatory actions are its ability to reduce inflammatory pathways and Toll-like receptors activation. The safety profile is favorable. In spite of its low frequency, retinal toxicity is potentially severe. In systemic lupus erythematous HCQ therapy reduces activity, the accrual of organ damage, risk of infections and thrombosis and improves the cardiometabolic profile. It contributes to induce lupus nephritis remission, spares steroid use and increases survival rates. In rheumatoid arthritis, it improves cardiometabolic risk and has a favorable effect in joint inflammation. In Sjogren's syndrome, an increased lacrimal quality as well as an improvement in objective and subjective inflammatory markers has been demonstrated with HCQ. In Antiphospholipid Syndrome, HCQ is effective in primary and secondary thrombosis prevention. The effectiveness of the drug in other systemic autoimmune diseases is less established. HCQ therapy may improve dermatological manifestations in Dermatomyositis and may have a positive effects in the treatment of Sarcoidosis and Still disease.es_ES
dc.language.isoenges_ES
dc.publisherSociedad Médica Santiagoes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectantiphospohlipid syndromees_ES
dc.subjectautoimmune diseaseses_ES
dc.subjecthydroxychloroquinees_ES
dc.subjectsystemic lupus erythematosuses_ES
dc.subjectrheumatoid arthritises_ES
dc.subjectSjogren's syndromees_ES
dc.subjectmodifying antirheumatic drugses_ES
dc.subjectprimary Sjogren syndromees_ES
dc.subjectrheumatooid-arthritises_ES
dc.subjectantiphospholipid antibodieses_ES
dc.subjectEULAR recommendationses_ES
dc.subjecttherapyes_ES
dc.subjectriskes_ES
dc.subjectantimalarianses_ES
dc.subjectanticoagulantes_ES
dc.titleHidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicases_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderCreative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution Licensees_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872016000200012&lng=en&nrm=iso&tlng=enes_ES
dc.identifier.doi10.4067/S0034-98872016000200012
dc.departamentoesMedicinaes_ES
dc.departamentoeuMedikuntzaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License
Except where otherwise noted, this item's license is described as Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License